Bridge Investment Fund

BucketFeet, Inc., based in Chicago, Illinois, is a direct-to-consumer footwear brand that specializes in artist-designed shoes for men, women, and children. Founded in 2011, the company collaborates with a global community of artists to create unique, limited-edition sneakers, with each pair featuring a different artist's design. BucketFeet operates an online platform where customers can order shoes that are printed only after they are purchased, thus reducing unnecessary environmental waste associated with traditional manufacturing cycles. In addition to footwear, the company also offers apparel such as tees, hoodies, and socks. Through its innovative approach, BucketFeet aims to foster meaningful conversations and empower artists to share their stories through the medium of shoes, serving as a canvas for diverse artistic expression. As of late 2017, BucketFeet operates as a subsidiary of SkinnyCorp, LLC.

EarlySense develops signal-processing technology. The company's lead product, EverOn, a contact-free early detection patient supervision system that measures, records, displays, and alerts heart and respiration rates, as well as bed entries and exits, patient motion, and quality of sleep from under the mattress. EarlySense Ltd. was founded in 2004 and is based in Ramat Gan, Israel with a research and development facility in Israel; and marketing offices in Boston, Massachusetts.

EarlySense develops signal-processing technology. The company's lead product, EverOn, a contact-free early detection patient supervision system that measures, records, displays, and alerts heart and respiration rates, as well as bed entries and exits, patient motion, and quality of sleep from under the mattress. EarlySense Ltd. was founded in 2004 and is based in Ramat Gan, Israel with a research and development facility in Israel; and marketing offices in Boston, Massachusetts.

Navotek Medical develops real-time innovative tracking and navigation solutions for medical applications. The first application is in the oncology field, providing tumor localization and tracking for optimal radiation therapy. Navotek’s solution will allow for safer and more effective treatment, improving the chances of tumor eradication and decreasing the rate of complications. In addition, it will potentially improve the efficiency of the treatment procedure by shortening individual sessions as well as entire treatment courses. This will increase the radiation rooms’ throughput which will translate into increased earnings for the hospital.

CritiSense, Ltd. is a medical technology company that specializes in the real-time monitoring of patients' metabolic states, particularly during surgical procedures and in intensive care units. Founded in 2004 and based in Giv'at Shmu'el, Israel, the company has developed the CritiView, a sophisticated monitoring system that provides continuous, real-time data through the assessment of four physiological parameters at the tissue level. This device enables healthcare professionals, including surgeons, anesthesiologists, and ICU caregivers, to identify imbalances in tissue and body vitality by monitoring mitochondrial function, microcirculatory blood flow, and oxygen saturation. The technology, rooted in the expertise of co-founder Professor Avraham Mayevsky, enhances surgical outcomes and patient care by facilitating informed clinical decisions based on comprehensive physiological insights.